Literature DB >> 19626590

Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3.

Ryuta Tanimoto1, Masakiyo Sakaguchi, Fernando Abarzua, Ken Kataoka, Kaoru Kurose, Hitoshi Murata, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh.   

Abstract

We have recently shown that an adenovirus carrying REIC/Dkk-3 (Ad-REIC) exhibits a potent tumor-specific cell-killing function for various human cancers. It has also become evident that some human cancers are resistant to Ad-REIC-induced apoptosis. The aim of the present study was to determine the molecular mechanisms of resistance to Ad-REIC. First, we isolated resistant clones from a human prostate cancer cell line, PC3, after repeated exposure to Ad-REIC. Infection efficiency of the adenovirus vector and expression level of REIC/Dkk-3 in the resistant clones were similar to those in the parental PC3 cells. By screening for alteration in levels and functional status of proteins involved in Ad-REIC-induced apoptosis, we found that BiP/GRP78, an ER-residing chaperone protein, was expressed at higher levels consistently among resistant cells. Expression levels of BiP and rates of apoptosis induced by Ad-REIC were inversely correlated. Down-regulation of BiP with siRNA sensitized the resistant cells to Ad-REIC in vivo as well as in culture. These results indicate that BiP is a major determinant of resistance to Ad-REIC-induced apoptosis. Thus BiP is useful for diagnosis of inherent and acquired resistance of cancers and also as a target molecule to overcome resistance to the gene therapeutic Ad-REIC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19626590     DOI: 10.1002/ijc.24764

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma.

Authors:  Yosuke Miura; Kyoichi Kaira; Reiko Sakurai; Hisao Imai; Yoshio Tomizawa; Noriaki Sunaga; Koichi Minato; Takeshi Hisada; Tetsunari Oyama; Masanobu Yamada
Journal:  Int J Clin Oncol       Date:  2017-05-26       Impact factor: 3.402

2.  Expression analysis of Dickkopf-related protein 3 (Dkk3) suggests its pleiotropic roles for a secretory glycoprotein in adult mouse.

Authors:  Junji Inoue; Hirofumi Fujita; Tetsuya Bando; Yoichi Kondo; Hiromi Kumon; Hideyo Ohuchi
Journal:  J Mol Histol       Date:  2016-11-19       Impact factor: 2.611

3.  The induction of antigen-specific CTL by in situ Ad-REIC gene therapy.

Authors:  Y Ariyoshi; M Watanabe; S Eikawa; C Yamazaki; T Sadahira; T Hirata; M Araki; S Ebara; Y Nasu; H Udono; H Kumon
Journal:  Gene Ther       Date:  2016-02-02       Impact factor: 5.250

4.  Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.

Authors:  Xiangyu Zhang; Zelai He; Longquan Xiang; Liang Li; Haiyan Zhang; Fanzhong Lin; Hongying Cao
Journal:  Drug Des Devel Ther       Date:  2019-04-29       Impact factor: 4.162

5.  Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.

Authors:  Christoph Zenzmaier; Natalie Sampson; Eugen Plas; Peter Berger
Journal:  Prostate       Date:  2013-06-14       Impact factor: 4.104

6.  Dramatic increase in expression of a transgene by insertion of promoters downstream of the cargo gene.

Authors:  Masakiyo Sakaguchi; Masami Watanabe; Rie Kinoshita; Haruki Kaku; Hideo Ueki; Junichiro Futami; Hitoshi Murata; Yusuke Inoue; Shun-Ai Li; Peng Huang; Endy Widya Putranto; I Made Winarsa Ruma; Yasutomo Nasu; Hiromi Kumon; Nam-Ho Huh
Journal:  Mol Biotechnol       Date:  2014-07       Impact factor: 2.695

7.  A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy.

Authors:  Tetsuo Oka; Kazuhiko Kurozumi; Yosuke Shimazu; Tomotsugu Ichikawa; Joji Ishida; Yoshihiro Otani; Toshihiko Shimizu; Yusuke Tomita; Masakiyo Sakaguchi; Masami Watanabe; Yasutomo Nasu; Hiromi Kumon; Isao Date
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.